

# ANCO FAX News

Association of Northern California Oncologists  
Post Office Box 151109, San Rafael, California 94915-1109  
Voice: (415) 472-3960 • FAX: (415) 472-3961  
[execdir@anco-online.org](mailto:execdir@anco-online.org) • [www.anco-online.org](http://www.anco-online.org)

Vol. 16, No. 16

August 25<sup>th</sup>, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html).

#### In this issue:

- MACRA MIPS Resources
- ANCO's 2017 Professional Education Meeting & 3Q2017 Hematologic Malignancies Updates
- ANCO Young Investigator Award

#### The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.

The next regular *ANCO FAX News* will be published on September 15<sup>th</sup>. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; [execdir@anco-online.org](mailto:execdir@anco-online.org).

**The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!**

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

## ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

### **ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues**

CMS has released its proposed CY2018 *Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) rules*. Read the proposed rule at [www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment](http://www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment); read the fact sheet at [www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html](http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html). Major changes include a reduction in payments to hospitals participating in 340B under OPPS. Overall, physician payment rates will increase by .31% in CY2018 compared to CY2017, including an estimated 1% increase for radiation oncology. Read Bobbi Buell's summary of the proposed rule at [www.anco-online.org/BBMPFS2018Analysis.pdf](http://www.anco-online.org/BBMPFS2018Analysis.pdf).

CMS is readying a fraud prevention initiative that removes *Social Security Numbers* from Medicare cards to help combat identity theft and safeguard taxpayer dollars. The new cards will use a unique, randomly-assigned number called a *Medicare Beneficiary Identifier (MBI)* to replace the *Social Security-based Health Insurance Claim Number (HICN)* currently used on the Medicare card. CMS will begin mailing new cards in April 2018. For more information, visit the CMS *Social Security Removal Initiative (SSNRI)* website at [www.cms.gov/medicare/ssnri/](http://www.cms.gov/medicare/ssnri/).

The *Medicare Quality Payment Program (QPP)*, established by the *Medicare Access and CHIP Reauthorization Act (MACRA)*, began on January 1<sup>st</sup>. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit [qpp.cms.gov](http://qpp.cms.gov) for more information. In addition, CMS is now accepting hardship exceptions from the QPP for the 2017 reporting year based on insufficient internet connectivity, extreme and uncontrollable circumstances, and lack of control over the availability of certified EHR technology. Learn more at [qpp.cms.gov/about/hardship-exception](http://qpp.cms.gov/about/hardship-exception).

CMS has issued a proposed rule that would make changes in the second year of the QPP. The proposed rule "aims to simplify the program, especially for small, independent, and rural practices." Read the CMS fact sheet at [qpp.cms.gov/docs/QPP\\_Proposed\\_Rule\\_for\\_QPP\\_Year\\_2.pdf](http://qpp.cms.gov/docs/QPP_Proposed_Rule_for_QPP_Year_2.pdf); and, read Bobbi Buell's analysis at [www.anco-online.org/BBMIPS2018.pdf](http://www.anco-online.org/BBMIPS2018.pdf). ASCO submitted comments to CMS on the proposed rule arguing that its data show that the median financial penalty for oncology practices under the proposal would range from 14-23%, well beyond the CMS-envisioned 4% penalty. ASCO urged CMS to refrain from implementing such a policy at any point in time. In addition, ASCO urged CMS to implement multiple oncology-focused APMs, including its own PCOP model. Read ASCO's comments at [www.asco.org/sites/new-www.asco.org/files/content-files/QPP-2018-Proposed-Rule-Comments.pdf](http://www.asco.org/sites/new-www.asco.org/files/content-files/QPP-2018-Proposed-Rule-Comments.pdf); read ASH's comments at [www.hematology.org/Advocacy/Testimony.aspx](http://www.hematology.org/Advocacy/Testimony.aspx).

Unsure of your MIPS participation status? Clinicians can now use an interactive tool on the CMS *Quality Payment Program* website to determine if they should participate in MIPS.

Visit [qpp.cms.gov](http://qpp.cms.gov) > Check Now, enter your NPI and information will then be provided on whether or not you should participate in MIPS in 2017 and where to find resources.

**CMS is encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP.** To subscribe to the QPP listserv, go to [qpp.cms.gov](http://qpp.cms.gov) and select "Subscribe to Email Updates" at the bottom of the page.

**ASCO is pleased to announce that its *Quality Oncology Practice Initiative (QOPI) Qualified Clinical Data Registry (QCDR)* is now available for CMS MIPS reporting effective July 1<sup>st</sup>.** By using the QOPI QCDR for MIPS reporting, practices will be able to report on one measure for one patient in 2017 to avoid cuts to Medicare reimbursements in 2019. Express your interest in participating in the QOPI QCDR by e-mailing [qopi@asoc.org](mailto:qopi@asoc.org). Once registration is officially open, practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit [www.instituteforquality.org/qopi/about/quality-reporting](http://www.instituteforquality.org/qopi/about/quality-reporting). Registration closes October 1<sup>st</sup>.

**ASCO's series of webinars to guide oncology practices to successful quality reporting** are available at [www.asco.org/macra](http://www.asco.org/macra) > MACRA Webinar Series. **ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status** at [www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status](http://www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status). For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to [www.asco.org/macra](http://www.asco.org/macra). ASH's updated MACRA webpage is at [www.hematology.org/Clinicians/7427.aspx](http://www.hematology.org/Clinicians/7427.aspx).

**ASH members can now sign up to report data for the Medicare MIPS through *Healthmonix's***

**MIPSPRO, a 2017 Qualified MIPS Registry.** Learn more at [healthmonix.com/mips-pro/](http://healthmonix.com/mips-pro/).

**The *American Medical Association (AMA)* has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a Medicare payment penalty with basic reporting.*** The video and other AMA resources are available at [www.ama-assn.org/qpp-reporting](http://www.ama-assn.org/qpp-reporting).

**CMA's *Center for Economic Services (CES)* has published an update to its MACRA preparation checklist entitled *MACRA: What Should I Do Now to Prepare?*** available at [www.cmanet.org/macra](http://www.cmanet.org/macra).

**The *Department of Health and Human Services (DHHS)* has delayed until July 2018 a final 340B rule that would penalize pharmaceutical companies that knowingly overcharge hospitals for drugs purchased through the program.** The *Advisory Panel on Hospital Outpatient Payment* has asked CMS to rescind its proposal to pay hospitals 22.5% less than ASP for drugs acquired under the program.

### ***CMA, MOASC, and State Legislative & Regulatory Issues***

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf.** That advocate is the *California Medical Association (CMA)*. While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you.** The CMA's *Center for Economic Services (CES)* has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers. For membership, please call (916) 551-2042; for reimbursement assistance, please call

CMA's *Reimbursement Helpline* at (888) 401-5911.

**Forthcoming CMA webinars include:**

- MACRA: Guidance on Merit-Based Incentive Payment System (MIPS); September 20)
- Assembly Bill 72: How to Challenge the Interim Payment of Out-of-Network Services at In-Network Facilities (September 27)

Contact CMA's member help center at (800) 786-4262 or [memberservice@cmanet.org](mailto:memberservice@cmanet.org) for more information. Register online at [www.cmanet.org/events](http://www.cmanet.org/events).

***CMA Practice Resources (CPR)*** is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit [www.cmanet.org/cpr](http://www.cmanet.org/cpr) to subscribe.

***Noridian/JEMAC, DHCS/MediCal, & Private Payers***

***Noridian Administrative Services*** is the **Jurisdiction E (JE) Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at [med.noridianmedicare.com/web/jeb](http://med.noridianmedicare.com/web/jeb). Recent updates include:

- MLN Connects Provider eNews *Announcements*—CMS Releases Hospice Compare Website to Improve Consumer Experiences, Empower Patients; CMS Releases Updated Data on Medicare Hospice Utilization and Payment; SNF Quality Reporting Program Web-based Training Module Available; Beneficiary Notices: Large Print Forms Available *Claims, Pricers, and Codes*—2018 ICD-

10-CM Coding Guidelines and Conversion Table Available; PQRS: Feedback Reports and Informal Review Process for PY2016 Results Call-September 26; Physician Compare Call-September 28

*Publications*—Care Management Listening Session: Audio Recording and Transcript-New; Medicare Parts A & B Appeals Process Booklet-Revised; Chronic Care Management Services Changes for 2017 Fact Sheet-Reminder

- MolDX: Xpresys Lung Final LCD-Effective September 29, 2017
- ICD-10 Coding Revision to NCDs CR10184
- MolDX: LICAM Gene Sequencing, MolDX: SULT4A1 Genetic Testing, MolDX: PTCH1 Gene Testing--Billing and Coding Guidelines
- Contractor Status Codes (C-Status) Updates-Revised
- Radiopharmaceutical Fee Schedule 2017 Updates-Second Correction
- August Webinars-Register Now

*Noridian/JEMAC's* Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at [www.edissweb.com/cgp/news/index.html](http://www.edissweb.com/cgp/news/index.html).

**Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:**

- Duplicate Claims (September 13)
- Visit [med.noridianmedicare.com/web/jeb/education/training-events](http://med.noridianmedicare.com/web/jeb/education/training-events) for more information and to register.

**EDUCATION**

*[Editor's Note: ANCO organizes clinical and professional*

education meetings throughout the year and throughout Northern California.]

## **ANCO's 2017**

### **Professional Education Meeting**

ANCO will host its 2017 professional education meeting on September 6<sup>th</sup> at the *San José Fairmont*. The agenda will include *QPP/MACRA*, *ASCO's COME HOME Project*, *USP797/800*, and *California Legislative/Regulatory Updates*. Download the meeting announcement at [www.anco-online.org/ProfEduc2017.pdf](http://www.anco-online.org/ProfEduc2017.pdf).

### **ANCO's 2017 Hematologic Malignancies Updates**

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The second *Update* takes place on September 9<sup>th</sup> at the *Stanford Park Hotel* with Bruno Medeiros, M.D., *Stanford University*, Charalambos Andreadis, M.D., *University of California, San Francisco*, and Brian Sworder, M.D., *Stanford University*. The latest research on novel treatment modalities for leukemias and lymphomas, along with case studies for these diagnoses will be presented. These updates are supported by *Janssen Biotech*, *Merck*, *Pfizer Oncology*, and *Pharmacyclics*. Download the meeting announcement at [www.anco-online.org/3Q2017HemeMalig.pdf](http://www.anco-online.org/3Q2017HemeMalig.pdf).

### **SAVE THE DATE**

### **18<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach**

The *18<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18<sup>th</sup>. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to [www.multicancers.org](http://www.multicancers.org) to register your interest in receiving registration and housing information when it becomes available in the Fall.

### **Additional Education Meetings**

September 8-9<sup>th</sup>

*2017 ASH Meeting on Hematologic Malignancies*  
ASH

Chicago  
([www.hematology.org/Malignancies/Registration.aspx](http://www.hematology.org/Malignancies/Registration.aspx))

September 15<sup>th</sup>  
*2<sup>nd</sup> Annual Research Symposium*  
University of California Hematologic  
Malignancies Consortium  
San Francisco  
([www.uchmc.org](http://www.uchmc.org))

September 24-27<sup>th</sup>  
*59<sup>th</sup> Annual Meeting*  
ASTRO  
San Diego  
([www.astro.org](http://www.astro.org))

September 26<sup>th</sup>  
*Highlights from the 2017 ASCO Annual Meeting (Part I of Your Guide to the Latest Cancer Research and Treatment)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

September 27-28<sup>th</sup>  
*ASCO Advocacy Summit 2017: Lead, Engage, Influence*  
ASCO  
Alexandria  
([www.surveymonkey.com/r/AdvocacySummit2017](http://www.surveymonkey.com/r/AdvocacySummit2017))

September 28<sup>th</sup>  
*Highlights from the 2017 ASCO Annual Meeting (Part II of Your Guide to the Latest Cancer Research and Treatment)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 2<sup>nd</sup>  
*Treatment Update on Liver Cancer*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 4<sup>th</sup>  
*What's New in the Treatment of Waldenström's Macroglobulinemia (WM)*  
CancerCare Connect Education Workshop

([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 5<sup>th</sup>

*Progress in the Treatment of Indolent Non-Hodgkin Lymphoma*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 6<sup>th</sup>

*Update on Soft Tissue Sarcoma*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 6-7<sup>th</sup>

*12<sup>th</sup> Annual Congress: Hematologic Malignancies*  
NCCN

San Francisco

([www.nccn.org/professionals/meetings/hematological/default.aspx](http://www.nccn.org/professionals/meetings/hematological/default.aspx))

October 18-20<sup>th</sup>

*34<sup>th</sup> National Oncology Conference*

ACCC

Nashville

([www.accc-cancer.org/meetings/NOC2017.asp](http://www.accc-cancer.org/meetings/NOC2017.asp))

October 19<sup>th</sup>

*Living with Metastatic Breast Cancer*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

October 27-28<sup>th</sup>

*Palliative and Supportive Care in Oncology Symposium*

ASCO

San Diego

([www.pallonc.org](http://www.pallonc.org))

Please contact the ANCO office for more information about these meetings.

## ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

### **Board of Directors**

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and

professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for September 26<sup>th</sup>**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

### **Individual Member News**

The *Conquer Cancer Foundation* (CCF) of the *American Society of Clinical Oncology* (ASCO) is now accepting applications for the 2018 *Young Investigator Award* (YIA). The *Association of Northern California Oncologists* (ANCO) is funding one 2018 YIA for a qualified northern California applicant, and urges all eligible northern California physicians to apply. The YIA is a one-year, \$50,000 grant that provides research funding to promising physicians to support their transition from final years of training to faculty appointment and to encourage and promote quality research in clinical oncology. Applications in all areas of cancer research are accepted from U.S. and international applicants. For 2018, CCF has dedicated funding for the following areas: breast cancer, northern California researchers, global oncology, kidney cancer, lung cancer, pediatric cancer, sarcoma, and supportive care. Other areas of interest include cholangiocarcinoma, chronic lymphocytic leukemia, gynecological cancers, and melanoma. YIA applications opened on July 1<sup>st</sup> and are due by 11:50PM ET on September 21<sup>st</sup>. Eligibility criteria, award details, and the request for proposals are available on the CCF website ([www.conquer.org/young-investigator-award](http://www.conquer.org/young-investigator-award)). For questions about the YIA or assistance with your application, please e-mail [grants@conquer.org](mailto:grants@conquer.org).

**ASCO urges community oncologists to join ASCO's Leadership Development Program.**

Participants in this year-long leadership program will gain extensive exposure to the roles and mission of ASCO, its leadership, and the *Society's*

powerful place in developing the future of cancer care. Visit [www.asco.org/training-education/professional-development/leadership-development-program](http://www.asco.org/training-education/professional-development/leadership-development-program) for more information and to apply.

A current *Directory of Members* is available online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html) as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at [execdir@anco-online.org](mailto:execdir@anco-online.org) with any corrections, additions, and/or deletions.

### **Group Member News**

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, and *Palo Alto Medical Foundation* for their multi site group memberships.

### **Institutional Member News**

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

The *Stanford Cancer Center's MDS Center* is co-sponsoring a the MDS Foundation's Educational

**Patient-Caregiver Forum on Saturday, October 28.** The Forum takes place at 875 Blake Wilbur Drive, Room 2103, Stanford, CA 94305 from 9:30AM through 2PM.

### **Corporate Member News**

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals*  
*AMGEN • ARIAD Pharmaceuticals*  
*Astellas Oncology • AstraZeneca*  
*Bayer Healthcare Pharmaceuticals*  
*bioTheranostics*  
*Boehringer Ingelheim Pharmaceuticals*  
*Bristol-Myers Squibb Oncology*  
*Cardinal Health Specialty Solutions*  
*Celgene • Clovis Oncology • Daiichi Sankyo*  
*Eisai • EMD Serono • Exelixis*  
*Foundation Medicine • Genentech BioOncology*  
*Genomic Health • Gilead Sciences*  
*Guardant Health • Helsinn Oncology*  
*Heron Therapeutics • Incyte*  
*Janssen Oncology • Jazz Pharmaceuticals*  
*Kite Pharmaceuticals • Lilly Oncology • Merck*  
*nanoString • Novartis Oncology*  
*Oncology Supply/ION • Pfizer Oncology*  
*Pfizer US Biosimilars • Pharmacyclics*  
*Sandoz Biopharmaceuticals • Sanofi Genzyme*  
*Seattle Genetics • Taiho Oncology*  
*Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia*, *bioTheranostics*, *EMD Serono*, *Kite Pharmaceuticals*, and *Pfizer US Biosimilars* as new Corporate Members for 2017. *Dendreon*, *Genoptix Medical Laboratory*, *GenPath Oncology*, *Infinity Pharmaceuticals*, *Ipsen Biopharmaceuticals*, *Medivation*, *Merrimack Pharmaceuticals*, and *Prometheus Laboratories* did not renew their memberships for 2017. Please visit [www.anco-online.org/assistance.html](http://www.anco-online.org/assistance.html) for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member

practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

**AstraZeneca** informs ANCO that the *United States Food and Drug Administration* has approved Lynparza as a maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients, who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA status.

**Pfizer Oncology** informs ANCO that the *United States Food and Drug Administration* has approved *Wyeth Pharmaceutical's* Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

**Pfizer Oncology** is pleased to inform ANCO of the availability of online resources to support employers interested in managing cancer in the workplace. These online resources were developed in collaboration with Anthem, Cancer and Careers, and USBLN and are designed to either help support employees who are living with cancer so they can remain in the workplace or help transition them back to work. For more information, please contact your *Pfizer Oncology Key Account Manager* Ann Glasser at [ann.glasser@pfizer.com](mailto:ann.glasser@pfizer.com) or visit [www.workplacetransitions.org/](http://www.workplacetransitions.org/).

### **Clinical Trial News**

The ASCO Research Community Forum 2017 Annual Meeting is being held on September 24-25<sup>th</sup> at ASCO. The theme of this year's meeting is advancing cancer care through research partnerships. Register today at [www.asco.org/research-progress/research-community-forum/forum-annual-meeting?](http://www.asco.org/research-progress/research-community-forum/forum-annual-meeting?)

**UC Davis** brings the following clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 2 Study of MEDI4736 (durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic

Colorectal and NSCLC (PHII-155/NCT02888743). Principal Investigator: Arta Monjazebe, M.D.; Contact: Christina Devisser, (916) 734-1787

- A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia (PHI-95/NCT02890329). Principal Investigator: Brian Jonas, M.D.; Contact: Christina Romo, (916) 734-1455

Further information is available at [www.ucdmc.ucdavis.edu/cancer/clinical\\_trials/](http://www.ucdmc.ucdavis.edu/cancer/clinical_trials/).

**UC San Francisco** brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib and Dexamethasone (RVd) in Subjects With New Diagnosed Multiple Myeloma Eligible For High-Dose Chemotherapy and Autologous Stem Cell Transplantation (GRIFFIN; 54767414MMY2004). PI: Nina Shah, MD, (415) 353-2737, [nina.shah@ucsf.edu](mailto:nina.shah@ucsf.edu)

Further information is available at [cancer.ucsf.edu/trials](http://cancer.ucsf.edu/trials).

### **Publications, Resources, Services, & Surveys**

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to [apps.asco.org/oncology-practice-central/survey](http://apps.asco.org/oncology-practice-central/survey).

The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date and will continue to grow as more guidelines and tools are added.



Download the app at [www.asco.org/guidelines](http://www.asco.org/guidelines) or [www.asco.org/apps](http://www.asco.org/apps).

**ASCO has updated its clinical practice guideline for nausea and vomiting related to cancer treatment.** The update provides new evidence-based information on the appropriate use of olanzapine, NK1 receptor antagonists and dexamethasone. The guideline update is at [www.asco.org/supportive-care-guidelines](http://www.asco.org/supportive-care-guidelines). In addition, **ASCO has updated its NSCLC guidelines with new directives for genomic testing.** The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies. Read the updated guidelines at [www.asco.org/practice-guidelines/quality-guidelines/guidelines/lung-cancer](http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/lung-cancer).

**ASCO, the American Urological Association, the American Society for Radiation Oncology, and the Society of Urologic Oncology have issued a joint guideline on treatment of patients with muscle-invasive bladder cancer.** Learn more at [www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/25246](http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/genitourinary-cancer#/25246).

**ASCO's Clinical Affairs Department is dedicated to providing services, education, and resources to support oncology practices.** It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit [www.asco.org/practice-guidelines/practice-support](http://www.asco.org/practice-guidelines/practice-support).

**ASCO is launching its new Practice Engagement Program to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system.**

Building on an array of resources developed to help practices remain viable and thrive during this turbulent period, the new *Practice Engagement Team* will help participating practices learn more about the specific ASCO services and programs that can best support their needs. Learn more at [www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program-connects-practices-specific-resources](http://www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program-connects-practices-specific-resources).

**ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care.** PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to [www.asco.org/PracticeNET](http://www.asco.org/PracticeNET) for more information.

**The August 2017 issue of ASCO's Journal of Oncology Practice (JOP)** is available online and features articles entitled *Value-Based Calculators in Cancer: Current State and Challenges*; *2017 ASCO Quality Care Symposium: Nurturing a New and Growing Community of Practitioners*; *Special Series: Palliative Care*; *Enhancing Informed Consent for Physician Aid in Dying: Potential Role of Handout on Possible Benefits of Palliative Care*. Visit [jop.ascopubs.org](http://jop.ascopubs.org) for more information.

**ASCO and Innovative Oncology Business Solutions (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer.** ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit [www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come](http://www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come)

home.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at [www.accc-cancer.org/drugdatabase/](http://www.accc-cancer.org/drugdatabase/).

ACCC's enhanced set of *Financial Advocacy Network* resources are at [www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp](http://www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp). This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

**The cost of cancer care continues to be a top concern for patients and their healthcare providers. In response, ACCC has launched *The Financial Advocacy Boot Camp***, the first free online training program designed for all those who work to assist cancer patients in navigating financial issues related to their cancer treatment. Learn more at [www.accc-cancer.org/resources/FinancialAdvocacy-bootcamp.asp](http://www.accc-cancer.org/resources/FinancialAdvocacy-bootcamp.asp).

**ACCC's 2017 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges.** The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit [www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf](http://www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf) to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at [accc-fan-app.org](http://accc-fan-app.org). ***assistPoint* is your website for complimentary one-stop cancer Patient Assistance.** You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each

drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to [www.assistpoint.com](http://www.assistpoint.com) to learn more.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for central nervous system cancers (V1.2017), chronic lymphocytic leukemia/small lymphocytic lymphoma (V1.2018), gastric cancer (V3.2017), hairy cell leukemia (V1.2018), hepatobiliary cancers (V3.2017), Hodgkin lymphoma and B-cell lymphomas (chemotherapy order templates), smoking cessation (V2.2017). Go to [www.nccn.org](http://www.nccn.org) for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at [www.nccn.org/redirects/nicelines.asp?Type=general](http://www.nccn.org/redirects/nicelines.asp?Type=general).